Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

540 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
Schroen AT, Petroni GR, Wang H, Thielen MJ, Sargent D, Benedetti JK, Cronin WM, Wickerham DL, Wang XF, Gray R, Cohn WF, Slingluff CL, Djulbegovic B. Schroen AT, et al. Among authors: sargent d. Clin Trials. 2011 Oct;8(5):591-600. doi: 10.1177/1740774511419683. Epub 2011 Aug 30. Clin Trials. 2011. PMID: 21878447 Free PMC article.
Optimism bias leads to inconclusive results-an empirical study.
Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ. Djulbegovic B, et al. Among authors: sargent d. J Clin Epidemiol. 2011 Jun;64(6):583-93. doi: 10.1016/j.jclinepi.2010.09.007. Epub 2010 Dec 16. J Clin Epidemiol. 2011. PMID: 21163620 Free PMC article. Review.
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A; Adjuvant Colon Cancer End-points (ACCENT) Group. Sargent D, et al. Eur J Cancer. 2011 May;47(7):990-6. doi: 10.1016/j.ejca.2010.12.015. Epub 2011 Jan 21. Eur J Cancer. 2011. PMID: 21257306 Free PMC article.
A three-outcome design for phase II clinical trials.
Sargent DJ, Chan V, Goldberg RM. Sargent DJ, et al. Control Clin Trials. 2001 Apr;22(2):117-25. doi: 10.1016/s0197-2456(00)00115-x. Control Clin Trials. 2001. PMID: 11306150
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. Seymour L, et al. Among authors: sargent d. Clin Cancer Res. 2010 Mar 15;16(6):1764-9. doi: 10.1158/1078-0432.CCR-09-3287. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215557 Free PMC article.
Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M. van Rooijen KL, et al. Among authors: sargent dj. Eur J Cancer. 2018 Mar;91:99-106. doi: 10.1016/j.ejca.2017.12.014. Epub 2018 Jan 30. Eur J Cancer. 2018. PMID: 29353165
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.
Renfro LA, Grothey A, Kerr D, Haller DG, André T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group. Renfro LA, et al. Among authors: sargent dj. Ann Oncol. 2015 May;26(5):950-958. doi: 10.1093/annonc/mdv073. Epub 2015 Feb 19. Ann Oncol. 2015. PMID: 25697217 Free PMC article.
540 results